Status:
RECRUITING
The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Acute Pulmonary Embolism
Eligibility:
All Genders
18+ years
Brief Summary
From January 1, 2023 to December 30, 2023, patients who were suspected of pulmonary embolism and underwent CTPA examination at Nanyang Hospital of Southern Medical University were divided into pulmona...
Eligibility Criteria
Inclusion
- Voluntary signing of informed consent form;
- When signing the informed consent form, the age is equal to or greater than 18 years old, regardless of gender;
- From January 1, 2023 to December 30, 2023, the patient was diagnosed with suspected pulmonary embolism at the Southern Hospital of Southern Medical University and underwent enhanced pulmonary artery scanning examination.
Exclusion
- Patients with gastrointestinal bleeding, severe trauma, acute coronary syndrome, severe liver disease (childC grade), and coagulation dysfunction;
- Patients with pulmonary embolism diagnosed outside the hospital and regular anticoagulation;
- Patients undergoing regular anticoagulant therapy such as atrial fibrillation and valve replacement;
- Patients deemed unsuitable for participation in this study by the researchers.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT06192199
Start Date
January 1 2018
End Date
December 1 2026
Last Update
April 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang hospital of Southern Medical University
Guangzhou, Guangdong, China